GlassScriptPhysician profile
Jarreau Spencer S Chen
NPI 1205276458
$5,114.07
in general payments reported to CMS, 2019-2025
40 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $328 · 2021: $567 · 2022: $801 · 2023: $879 · 2024: $876 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.40 | 2019-2025 | Lupron Depot |
| Novo Nordisk INC | $615.69 | 2020-2025 | Sogroya, Wegovy, Norditropin |
| Kyowa Kirin, INC. | $424.31 | 2023-2025 | Crysvita |
| Neurocrine Biosciences, INC. | $315.07 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $274.14 | 2022-2025 | Skytrofa, Yorvipath |
| Xeris Pharmaceuticals, INC. | $228.32 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $214.55 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Medtronic, INC. | $186.99 | 2021-2025 | Minimed 780g |
| Tolmar, INC. | $170.36 | 2023-2025 | Fensolvi |
| Lilly USA, LLC | $163.78 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $161.90 | 2021-2023 | |
| Ucb, INC. | $159.83 | 2022-2025 | Fintepla, Briviact |
| Sanofi-Aventis U.S. LLC | $151.58 | 2023-2025 | |
| Rhythm Pharmaceuticals, INC. | $150.89 | 2022-2025 | Imcivree, Imcivree |
| Pfizer INC. | $108.26 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $97.68 | 2023-2024 | Triptodur, Triptodur |
| Tandem Diabetes Care, INC. | $96.73 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $95.87 | 2021-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $87.33 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Soleno Therapeutics, INC. | $58.31 | 2025 | Vykat Xr |
| Genzyme Corporation | $56.77 | 2023 | |
| Cequr Corporation | $54.95 | 2024 | Cequr Simplicity |
| Biomarin Pharmaceutical INC. | $54.23 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $48.81 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $38.63 | 2022 | |
| Mannkind Corporation | $34.85 | 2021 | |
| Alexion Pharmaceuticals, INC. | $33.10 | 2021-2024 | Strensiq |
| Rare Disease Therapeutics, INC. | $30.48 | 2024 | Purixan |
| Ironwood Pharmaceuticals, INC | $29.08 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.77 | 2024 | Dupixent |
| Qol Medical, LLC | $23.26 | 2024 | Sucraid |
| Neurelis, INC. | $23.22 | 2024 | Valtoco |
| Endo Pharmaceuticals INC. | $21.31 | 2023 | Supprelin |
| Gilead Sciences, INC. | $19.42 | 2021 | |
| Lifescan, INC. | $18.17 | 2020 | |
| Immedica Pharma US, INC. | $17.50 | 2023 | |
| Zogenix INC. | $17.19 | 2021 | |
| Zealand Pharma US, INC. | $16.48 | 2022 | |
| Insulet Corporation | $14.57 | 2019 | |
| Cranial Technologies, INC | $14.29 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarreau Spencer Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.